Raymond James & Associates Anavex Life Sciences Corp. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Raymond James & Associates holds 11,631 shares of AVXL stock, worth $130,616. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,631Holding current value
$130,616% of portfolio
0.0%Shares
5 transactions
Others Institutions Holding AVXL
# of Institutions
157Shares Held
27.4MCall Options Held
515KPut Options Held
838K-
Black Rock Inc. New York, NY6.39MShares$71.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.74MShares$53.2 Million0.0% of portfolio
-
State Street Corp Boston, MA3.07MShares$34.4 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.88MShares$21.1 Million0.0% of portfolio
-
Nwam LLC Mercer Island, WA910KShares$10.2 Million0.32% of portfolio
About ANAVEX LIFE SCIENCES CORP.
- Ticker AVXL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,942,800
- Market Cap $875M
- Description
- Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...